RECRUITINGOBSERVATIONAL

Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease

A Risk-predictive Model for Frequent Acute Exacerbation Phenotype in Patients With Severe Chronic Obstructive Pulmonary Disease

About This Trial

This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for potential diagnostic biomarkers in patients with frequent acute exacerbation and controls with non frequent acute exacerbation; Construct a frequent acute exacerbation risk prediction model using random forest, support vector machine, and BP neural network models. The development of this study will provide valuable references for the clinical classification and prognosis evaluation of chronic obstructive pulmonary disease (COPD), and improve the health level of COPD patients by further searching for treatable targets.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC\<70%, FEV1% predicted value ≤ 50% after Bronchiectasis) 2. Age\>40 years old 3. COPD stable for more than 4 weeks 4. Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month 5. Patient informed and signed consent form Who Should NOT Join This Trial: 1. Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis 2. Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune conditions (where your immune system attacks your own body)) 3. History of chronic diarrhea or constipation 4. History of Gastrointestinal Surgery 5. Using probiotics or antibiotics within the past 4 weeks 6. No history of using oral hormones or traditional Chinese medicine in the past three months 7. Pregnancy or lactation Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC\<70%, FEV1% predicted value ≤ 50% after Bronchiectasis) 2. Age\>40 years old 3. COPD stable for more than 4 weeks 4. Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month 5. Patient informed and signed consent form Exclusion Criteria: 1. Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis 2. Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease) 3. History of chronic diarrhea or constipation 4. History of Gastrointestinal Surgery 5. Using probiotics or antibiotics within the past 4 weeks 6. No history of using oral hormones or traditional Chinese medicine in the past three months 7. Pregnancy or lactation

Locations (1)

Beijing Chaoyang Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China